Abstract Objective To evaluate the early risk factors for death in neonates with persistent pulmonary hypertension of the newborn (PPHN) treated with inhaled nitric oxide (iNO). Methods A retrospective analysis was performed on 105 infants with PPHN (gestational age ≥34 weeks and age <7 days on admission) who received iNO treatment in the Department of Neonatology, Children's Hospital of Nanjing Medical University, from July 2017 to March 2021. Related general information and clinical data were collected. According to the clinical outcome at discharge, the infants were divided into a survival group with 79 infants and a death group with 26 infants. Univariate and multivariate Cox regression analyses were used to evaluate the risk factors for death in infants with PPHN treated with iNO. The receiver operating characteristic (ROC) curve was used to calculate the cut-off values of the factors in predicting the death risk. Results A total of 105 infants with PPHN treated with iNO were included, among whom 26 died (26/105, 24.8%). The multivariate Cox regression analysis showed that no early response to iNO (HR=8.500, 95%CI: 3.024-23.887, P<0.001), 1-minute Apgar score ≤3 points (HR=10.094, 95%CI: 2.577-39.534, P=0.001), a low value of minimum PaO2/FiO2 within 12 hours after admission (HR=0.067, 95%CI: 0.009-0.481, P=0.007), and a low value of minimum pH within 12 hours after admission (HR=0.049, 95%CI: 0.004-0.545, P=0.014) were independent risk factors for death. The ROC curve analysis showed that the lowest PaO2/FiO2 value within 12 hours after admission had an area under the ROC curve of 0.783 in predicting death risk, with a sensitivity of 84.6% and a specificity of 73.4% at the cut-off value of 50, and the lowest pH value within 12 hours after admission had an area under the ROC curve of 0.746, with a sensitivity of 76.9% and a specificity of 65.8% at the cut-off value of 7.2. Conclusions Infants with PPHN requiring iNO treatment tend to have a high mortality rate. No early response to iNO, 1-minute Apgar score ≤3 points, the lowest PaO2/FiO2 value <50 within 12 hours after admission, and the lowest pH value <7.2 within 12 hours after admission are the early risk factors for death in such infants. Monitoring and evaluation of the above indicators will help to identify high-risk infants in the early stage.
QIAN Ai-Min,ZHU Wen,YANG Yang et al. Early risk factors for death in neonates with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide[J]. CJCP, 2022, 24(5): 507-513.
QIAN Ai-Min,ZHU Wen,YANG Yang et al. Early risk factors for death in neonates with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide[J]. CJCP, 2022, 24(5): 507-513.
Steurer MA, Baer RJ, Oltman S, et al. Morbidity of persistent pulmonary hypertension of the newborn in the first year of life[J]. J Pediatr, 2019, 213: 58-65.e4. PMID: 31399244. DOI: 10.1016/j.jpeds.2019.06.053.
Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes[J]. Pediatrics, 2000, 105(1 Pt 1): 14-20. PMID: 10617698. DOI: 10.1542/peds.105.1.14.
Nakwan N, Jain S, Kumar K, et al. An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: incidence, etiology, diagnosis, treatment and outcome[J]. J Matern Fetal Neonatal Med, 2020, 33(12): 2032-2037. PMID: 30318951. DOI: 10.1080/14767058.2018.1536740.
Lai MY, Chu SM, Lakshminrusimha S, et al. Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn[J]. Pediatr Neonatol, 2018, 59(1): 15-23. PMID: 28923474. DOI: 10.1016/j.pedneo.2016.09.011.
Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group[J]. N Engl J Med, 2000, 342(7): 469-474. PMID: 10675427. DOI: 10.1056/NEJM200002173420704.
Macrae DJ, Field D, Mercier JC, et al. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus[J]. Intensive Care Med, 2004, 30(3): 372-380. PMID: 14722629. DOI: 10.1007/s00134-003-2122-3.
DiBlasi RM, Myers TR, Hess DR. Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure[J]. Respir Care, 2010, 55(12): 1717-1745. PMID: 21122181.
Zhao Y, Liang L, Liu G, et al. Asphyxia and neonatal respiratory distress syndrome are independent predictors of the non-response to inhaled nitric oxide in the newborns with PPHN[J]. Front Pediatr, 2021, 9: 665830. PMID: 34095030. PMCID: PMC8172584. DOI: 10.3389/fped.2021.665830.
Hwang SJ, Lee KH, Hwang JH, et al. Factors affecting the response to inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn infants[J]. Yonsei Med J, 2004, 45(1): 49-55. PMID: 15004868. DOI: 10.3349/ymj.2004.45.1.49.
Morel AA, Shreck E, Mally PV, et al. Clinical characteristics and factors associated with term and late preterm infants that do not respond to inhaled nitric oxide (iNO)[J]. J Perinat Med, 2016, 44(6): 663-668. PMID: 26352080. DOI: 10.1515/jpm-2015-0210.
Bischoff AR, Giesinger RE, Neary E, et al. Clinical and echocardiography predictors of response to inhaled nitric oxide in hypoxemic term and near-term neonates[J]. Pediatr Pulmonol, 2021, 56(5): 982-991. PMID: 33434418. DOI: 10.1002/ppul.25252.
Khemani RG, Rubin S, Belani S, et al. Pulse oximetry vs. PaO2 metrics in mechanically ventilated children: Berlin definition of ARDS and mortality risk[J]. Intensive Care Med, 2015, 41(1): 94-102. PMID: 25231293. DOI: 10.1007/s00134-014-3486-2.
Khemani RG, Thomas NJ, Venkatachalam V, et al. Comparison of SpO2 to PaO2 based markers of lung disease severity for children with acute lung injury[J]. Crit Care Med, 2012, 40(4): 1309-1316. PMID: 22202709. DOI: 10.1097/CCM.0b013e31823bc61b.
Khemani RG, Smith LS, Zimmerman JJ, et al. Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference[J]. Pediatr Crit Care Med, 2015, 16(5 Suppl 1): S23-S40. PMID: 26035358. DOI: 10.1097/PCC.0000000000000432.
Nu?ez A, Benavente I, Blanco D, et al. Oxidative stress in perinatal asphyxia and hypoxic-ischaemic encephalopathy[J]. An Pediatr (Engl Ed), 2018, 88(4): 228.e1-228.e9. PMID: 28648366. DOI: 10.1016/j.anpedi.2017.05.005.
Lakshminrusimha S, Saugstad OD. The fetal circulation, pathophysiology of hypoxemic respiratory failure and pulmonary hypertension in neonates, and the role of oxygen therapy[J]. J Perinatol, 2016, 36 Suppl 2: S3-S11. PMID: 27225963. DOI: 10.1038/jp.2016.43.
